Brazelton A, Yande S, Pope R, Johnson ML, Musher B, Trivedi MV. Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers. Ann Gastroenterol. 2022 Mar;35(2):182-6. doi: 10.20524/aog.2022.0688.
Liu SY, Trope GE, Buys YM, El-Defrawy SR, Khan AM, Jin YP. Visual impairment and the Ontario disability support program. Can J Ophthalmol. 2020 Jun;55(3):212-20. doi: 10.1016/j.jcjo.2019.12.009
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatology. 2019 Nov 6;19(1):15. doi: 10.1186/s12895-019-0095-3
Castellsague J, García-Rodríguez LA, Duque A, Perez-Gutthann S. Risk of severe cutaneous disorders in users of oral antifungals. BMC Dermatology. 2002 Nov 28;2(14). doi: 10.1186/1471-5945-2-14
Castellsague J, Garcia-Rodriuez LA, Duque A, Perez S. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatology. 2002;2:14.